839.1000 -7.05 (-0.83%)
NSE Jan 01, 2026 10:24 AM
Volume: 7,976
 

839.10
-0.83%
Deven Choksey
We maintain a positive FY26E outlook, expecting sustained double-digit growth across US, Ex-US, and RoW businesses. Growth across regions will be majorly driven by a healthy US pipeline, strategic expansion in RoW, and improved execution across India.
Alembic Pharmaceuticals Ltd. is trading below all available SMAs
More from Alembic Pharmaceuticals Ltd.
Recommended